Author Archives: Bruno Quinney

#AI #Business #Genomics #Lab automation #SLAS2026

Lab automation strong despite global challenges

The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in US drug pricing and tariffs, led to spending dips and nervousness throughout the sector.   SLAS2026 is a key point in the drug discovery calendar,… Read More

#Exclusive Content #Opinion

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

Human heart
#Cardiovascular disease #Drug development #Heart disease #Preclinical development

Human-first heart development

Ronald A Li, CEO and Co-Founder at Medera, explores how human-centred preclinical models are transforming cardiovascular drug development. When we published our previous article in Drug Discovery World last September, we argued that human-based mini-Heart technology could fundamentally reshape cardiovascular drug development by reducing reliance on animal models and improving translational predictability. That argument, grounded in strong science, ultimately required patient validation.  Today, that validation is emerging at scale.  … Read More

#Exclusive Content

Patient holding pill in hand
#ALS #Fast Track designation #FDA #Spinogenix

FDA grants Fast Track Designation to ALS pill 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for amyotrophic lateral sclerosis (ALS).  Tazbentetol, developed by biopharmaceutical company Spinogenix, is a once-a-day pill with potential to restore synapses, the key connections between neurons that allow people to think, plan, remember and control movement. … Read More

#News #Regulatory

Handshake jigsaw puzzle
#Autoimmune disease #Genomics #T cell

Genomics and Greywolf partner on autoimmune disease treatments 

Techbio company Genomics has partnered with biotech company Greywolf Therapeutics to advance novel antigen modulation treatments to treat autoimmune diseases.  Under the agreement, Genomics is set to curate and analyse large-scale genetic datasets to assess how variants of the ERAP (Endoplasmic Reticulum Aminopeptidases) enzymes influence disease risk across multiple autoimmune conditions. … Read More

#Business & Investment #News

#Autoimmune disease #National Institute for Health and Care Excellence (NICE) #UCB

NICE recommends Rystiggo for rare autoimmune disease 

The National Institute for Health and Care Excellence (NICE) has recommended Rystiggo (rozanolixizumab) as a treatment for adults with antibody-positive generalised myasthenia gravis (gMG).  Rystiggo is the first targeted therapy for gMG, a rare, chronic autoimmune neuromuscular disease. The condition is characterised by fluctuating muscle weakness and fatigue and can lead to difficulties with vision,… Read More

#News

CT scans of the brain
#Alzheimer's #Clinical trial

First patient dosed in Alzheimer’s agitation treatment 

The first patient has been dosed with a treatment for agitation in patients with Alzheimer’s disease (AD) dementia.  The Phase II/III SERENADA trial is evaluating the efficacy and safety of Deraphan, developed by biopharmaceutical company Exciva.  Deraphan is a combination of two clinically validated products: dextromethorphan, an NMDA… Read More

#News

#Cancer research #Oncology #T cell #Tumour biology #Tumour microenvironment (TME)

The missing link in treating cancer

Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this aggressive cancer.  For years, the conversation around pancreatic cancer has focused on the tumour itself, the "broken" cells that won't stop growing. In 2026,… Read More

#Exclusive Content

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Woman using an asthma inhaler
#Asthma #AstraZeneca #FDA

FDA approves first asthma triple therapy in US

The US Food and Drug Administration (FDA) has approved the first and only triple therapy for patients 12 years and older with asthma.  AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older.   Breztri is… Read More

#News #Regulatory

MRI of the brain
#epilepsy #Neurology #University College London

EpilepsyGTx appoints Co-Founder Dimitri Kullman as CSO 

Biotechnology company EpilepsyGTx has appointed Professor Dimitri Kullman as Chief Scientific Officer.  As a Co-Founder of EpilepsyGTx, the company says Kullmann’s role as CSO will shape and execute scientific strategy, setting research priorities and overseeing the delivery of its pipeline programmes.  EpilepsyGTx sees Kullmann as an internationally recognised leader in… Read More

#News

Stomach pain
#EnteroBiotix #Gastroenterology #Irritable Bowel Syndrome #UK

EnteroBiotix secures £19m to advance IBS treatment 

EnteroBiotix has announced it has secured £19 million ($26 million) in financing to advance a treatment for irritable bowel syndrome.  The biopharmaceutical company is set to use the investment to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic. EBX-102-02 will be advanced into Phase IIb development for… Read More

#Business & Investment #News

UK
#ABPI #AstraZeneca #Life sciences #UK

AstraZeneca investment strengthens UK’s position, CEO says 

AstraZeneca’s investment U-turn shows the UK is “a global destination for life sciences investment”, the ABPI’s Chief Executive has said.  Richard Torbett was speaking after AstraZeneca announced it would resume large-scale activity in the UK with a £300 million ($405 million) investment. The drugmaker had previously rolled back on investment in… Read More

#Business & Investment #News

FDA headquarters
#Clinical trial #FDA #Newron Pharmaceuticals #Schizophrenia

FDA pauses schizophrenia trial after patient death 

The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant.  Evenamide, developed by biopharmaceutical company Newron Pharmaceuticals, was being evaluated in the Phase III ENIGMA-TRS 2 study, targeting the modulation of excessive release of glutamate in patients suffering from… Read More

#News #Regulatory

#Drug discovery #Oncology #RadioMedix #Radiopharmaceuticals

The challenges and advancements in radiopharmaceuticals

DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important?    ED: One of the central challenges in radiopharmaceutical targeted alpha therapy… Read More

#Exclusive Content

#AI #Life sciences #Pistoia Alliance #R&D

Use of AI in drug R&D limited in life sciences, survey says 

The use of artificial intelligence is widespread across life sciences organisations but its use in drug research and development is limited, analysis finds.  Research by The Pistoia Alliance, a not-for-profit life sciences advocacy group, shows 30% of life sciences professionals say their organisation has implemented an enterprise-wide AI… Read More

#News